Unicycive Therapeutics Securities Fraud Lawsuit Lead Plaintiff Deadline Nears
Rosen Law Firm urges investors who purchased Unicycive Therapeutics securities to act before the November 2, 2026 deadline in relation to a potential securities fraud lawsuit.
New York – October 13, 2026 – Rosen Law Firm, a global investor rights law firm, is reminding purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) of an important deadline concerning a potential securities fraud lawsuit. Investors who acquired Unicycive securities between December 29, 2025, and June 29, 2026, inclusive, have until November 2, 2026, to seek lead plaintiff status in a class action.
The lawsuit alleges that the company made materially false and misleading statements or failed to disclose crucial information. This includes claims that Unicycive had not inspected its third-party manufacturing vendor's facility or audited its compliance with current good manufacturing practices. According to the complaint, this meant Unicycive lacked a reasonable basis to believe the vendor had resolved deficiencies cited by the U.S. Food and Drug Administration (FDA). The allegations suggest this presented an undisclosed risk that the FDA would require additional information about the vendor's manufacturing practices, potentially delaying the regulatory approval of oxylanthanum carbonate (OLC).
Rosen Law Firm notes that investors may be entitled to compensation without paying out-of-pocket fees through a contingency fee arrangement. By acting before the deadline, investors can seek to represent other class members and direct the litigation as lead plaintiff.
The class action targets a period during which Unicycive is accused of making misleading statements regarding its business operations and prospects. The lawsuit claims that when the true details emerged, investors suffered damages. Rosen Law Firm advises investors to select qualified counsel with a track record in securities class action leadership.
Until a class is certified, investors are not represented by counsel unless they retain one. Investors may also choose to remain absent class members and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.